- Home
- CLB vs ARVN Comparison
CLB vs ARVN Comparison
Compare CLB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- ARVN
- Stock Information
- Founded
- CLB 1936
- ARVN 2015
- Country
- CLB United States
- ARVN United States
- Employees
- CLB N/A
- ARVN N/A
- Industry
- CLB
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- ARVN Health Care
- Exchange
- CLB Nasdaq
- ARVN Nasdaq
- Market Cap
- CLB 553.2M
- ARVN 456.2M
- IPO Year
- CLB 1995
- ARVN 2018
- Fundamental
- Price
- CLB $12.87
- ARVN $7.80
- Analyst Decision
- CLB Hold
- ARVN Buy
- Analyst Count
- CLB 4
- ARVN 21
- Target Price
- CLB $15.00
- ARVN $20.53
- AVG Volume (30 Days)
- CLB 591.2K
- ARVN 1.8M
- Earning Date
- CLB 07-23-2025
- ARVN 07-29-2025
- Dividend Yield
- CLB 0.31%
- ARVN N/A
- EPS Growth
- CLB N/A
- ARVN N/A
- EPS
- CLB 0.59
- ARVN N/A
- Revenue
- CLB $517,796,000.00
- ARVN $426,900,000.00
- Revenue This Year
- CLB N/A
- ARVN $4.26
- Revenue Next Year
- CLB $2.92
- ARVN N/A
- P/E Ratio
- CLB $21.95
- ARVN N/A
- Revenue Growth
- CLB 1.32
- ARVN 498.74
- 52 Week Low
- CLB $10.15
- ARVN $5.90
- 52 Week High
- CLB $25.13
- ARVN $34.11
- Technical
- Relative Strength Index (RSI)
- CLB 58.35
- ARVN 54.65
- Support Level
- CLB $12.37
- ARVN $7.58
- Resistance Level
- CLB $13.19
- ARVN $8.31
- Average True Range (ATR)
- CLB 0.62
- ARVN 0.39
- MACD
- CLB 0.09
- ARVN 0.03
- Stochastic Oscillator
- CLB 82.60
- ARVN 64.75
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.